The Pro Medicus Ltd (ASX: PME) share price has been one of the stronger performers over the last six months, rising by 44%. It’s a valid question to ask whether Pro Medicus can rise much further.
Pro Medicus describes itself as a leading healthcare informatics company. It provides a full range of medical imaging software and services to hospitals, imaging centres and healthcare groups worldwide.
It offers a leading suite of radiology information systems (RIS), picture archiving and communication system (PACS), artificial intelligence and e-health solutions.
Strong recovery
Pro Medicus suffered a huge decline last year and early this year as the market worried about what AI could mean for the company’s future. However, the market seems to be a bit more positive about the situation.
It helps that the business continues to report an impressive set of numbers with its financials.
In the FY26 result, revenue grew 22.9% to $261.7 million, underlying operating profit (EBIT) grew 24.4% to $196.1 million and underlying net profit after tax (NPAT) rose 24.1% to $144.7 million.
The company has a significant presence in the US, so changes in foreign exchange rates can impact what it reports in Australian dollars. FY26 changes in currency hurt the financials.
If currency rates hadn’t changed, revenue would have increased 28.4% to $273.5 million, underlying EBIT would have gone up 30.6% to $206 million and underlying NPAT would have risen 32.5% to $154.5 million.
The impressive profit growth allowed the company to hike its payout by 25.5% to 37 cents per Pro Medicus share.
The future looks promising considering the underlying EBIT margin rose again to 74.9% in FY26, up from 74% in FY25. It continues to win sizeable contracts at an impressive pace, which is helping drive revenue.
Its latest contract win was a seven-year A$25 million contract with Valley Health, which includes the relatively new cardiology imaging offering. In that announcement, Pro Medicus said its pipeline is strong and spans all market segments.
How much could the Pro Medicus share price rise in the next year?
According to CMC Invest, there have been 10 analyst ratings on the business within the last three months.
A price target tells us where an analyst thinks a share price could go in the next 12 months. The average price target of those 10 ratings is $220.14, according to CMC Invest, suggesting a possible rise of 21% over the next year.
The most optimistic price target is $240, suggesting a possible rise of 32%.
So, analysts are excited about the future of the business and it could still be one to watch.
The post How much could the Pro Medicus share price rise in the next year? appeared first on The Motley Fool Australia.
Should you invest $1,000 in Pro Medicus right now?
Before you buy Pro Medicus shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Pro Medicus wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 1 August 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Warren Buffett’s playbook: 3 cheap ASX shares that could soar up to 60%
- 3 ASX shares I’d buy for the next 15 years
- Buy, hold, sell: Pro Medicus, Fortescue, CBA shares
- ASX 200 healthcare shares soar 9% amid notable FY26 reports from CSL, Pro Medicus
- Why Guzman Y Gomez, Pro Medicus and James Hardie shares are turning heads on Friday
Motley Fool contributor Tristan Harrison has positions in Pro Medicus. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.